Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine at a time when Omicron was the prevalent variant Children 5 through 11 years of age now authorized to
Weiter zum vollständigen Artikel bei "RSS Importer"